Adjuvant pembrolizumab improves RCC disease-free survival | Toni Choueiri
Вставка
- Опубліковано 25 жов 2024
- Toni Choueiri outlines the results of the phase 3 KEYNOTE-564 trial showing the benefit of adjuvant treatment with pembrolizumab in patients with high-risk renal cell carcinoma (3:03).
View more on Medicine Matters oncology: bit.ly/3fMzOa9